Related Experiment Video

Updated: May 17, 2026

Formulation and Characterization of Bioactive Agent Containing Nanodisks
07:58

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

Formulation and evaluation of indomethacin biomicroparticles

Sudeep Gupta1, Pawan Gaur, Kulwant Soam

  • 1Department of Pharmacy, Gyani Inder Singh Institute of Professional Studies, Dehradun, Uttarakhand, India.

Journal of Pharmacy & Bioallied Sciences
|October 16, 2012
PubMed

Insights

Researchers developed indomethacin microparticles using a novel, economical bio-polymer from Arachis hypogen (peanut). In vitro studies demonstrated successful drug release through an eggshell membrane, highlighting potential for controlled drug delivery systems.

Area of Science:

  • Biomaterials Science
  • Pharmaceutical Technology
  • Drug Delivery Systems

Background:

  • The development of novel drug delivery systems is crucial for improving therapeutic efficacy and patient compliance.
  • Bio-polymers offer a sustainable and biocompatible alternative to synthetic materials in pharmaceutical formulations.

Purpose of the Study:

  • To prepare indomethacin microparticles using a bio-polymer extracted from Arachis hypogen (peanut).
  • To evaluate the in vitro drug release profile of these microparticles using an eggshell membrane model.
  • To characterize the yield and particle size of the novel bio-polymer and resulting microparticles.

Main Methods:

  • Extraction of a bio-polymer from Arachis hypogen using a simplified, economical process.
  • Preparation of indomethacin microparticles incorporating the extracted bio-polymer.
  • In vitro drug release study conducted over 3 hours using an eggshell membrane as a diffusion barrier.
  • Analysis of drug concentration in release samples using UV spectroscopy at 320 nm.

Main Results:

  • A novel bio-polymer was successfully isolated from Arachis hypogen with a high % yield of 80%.
  • The prepared indomethacin microparticles exhibited a particle size range of 32-65 μm.
  • The in vitro drug release study demonstrated the capability of the microparticles to release indomethacin over the 3-hour period.

Conclusions:

  • Arachis hypogen is a viable source for an economical bio-polymer suitable for microparticle formulation.
  • The developed indomethacin microparticles show potential for use in controlled drug delivery applications.
  • The eggshell membrane model provides a useful in vitro method for assessing drug release from microparticulate systems.
Keywords:
Microparticlesbiomicroparticlesindomethacin

More Related Videos

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Related Concept Videos

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...
Modified-Release Drug Delivery Systems: Bioavailability01:30

Modified-Release Drug Delivery Systems: Bioavailability

Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...